CA 19-9 (pancreas, colon)

Carcinoma antigen 19-9 (CA 19-9) is a tumor marker often associated with gastrointestinal cancers, particularly pancreatic cancer. Its measurement, or the CA 19-9 analysis, provides valuable information in the diagnosis, monitoring of therapy, and detection of recurrences of these cancers. In this regard, the biochemical laboratory in Belgrade, IntroLab, is here to provide you with detailed information about this analysis and its specificities.

What is CA 19-9?

CA 19-9 is a tumor marker that refers to a specific antigen, or protein, that can be found in the tissues and bloodstream of certain patients. Specifically, CA 19-9 refers to a glycolipid antigen that is present in various tissues. This includes the gastrointestinal tract, pancreas, liver, gallbladder, and colon.

CA 19-9 Analysis: Clinical Significance

Besides pancreatic cancer, elevated levels of CA 19-9 can also be seen in other types of gastrointestinal tract cancers, including colon cancer and stomach cancer. This is important for early detection and monitoring the progression of these cancers.

Apart from cancer, CA 19-9 can be elevated in certain benign conditions. For example, in patients with cystic fibrosis, increased levels of this protein may indicate the presence of pancreatic damage. Also, in individuals with pancreatitis or acute hepatitis, high levels of the carcinoma antigen 19-9 marker may be a result of the inflammatory process in these organs.

Interpreting the Results

Normal reference values for CA 19-9 can vary depending on the laboratory but are usually below 37 U/mL.

As previously mentioned, elevated values may indicate the presence of certain cancers, especially pancreatic cancer. However, it is important to note that these values are not specific only to cancer and can also occur in other diseases. Therefore, additional diagnostic methods and clinical examinations are necessary for an accurate diagnosis.

Also, it should be considered that low levels of CA 19-9 do not exclude the presence of cancer. This tumor marker is not sensitive or specific enough for reliable cancer detection, especially in the early stages.

Accordingly, the final interpretation of the results should be carried out considering the complete clinical picture, results of other diagnostic tests, and individual characteristics of the patient. Always consult with a doctor who will provide the most accurate interpretation and thus establish an adequate diagnosis.